Ignite Creation Date:
2024-05-06 @ 2:37 AM
Last Modification Date:
2024-10-26 @ 11:20 AM
Study NCT ID:
NCT02080364
Status:
TERMINATED
Last Update Posted:
2021-05-07
First Post:
2014-02-25
Brief Title:
Evaluation of the Efficacy and Safety of Azeliragon TTP488 in Patients With Mild Alzheimers Disease
Sponsor:
vTv Therapeutics
Organization:
vTv Therapeutics
Study Overview
Official Title:
Randomized Double-blind Placebo Controlled Multi-center Registration Trial to Evaluate the Efficacy and Safety of Azeliragon TTP488 in Patients With Mild Alzheimers Disease Receiving Acetylcholinesterase Inhibitors andor Memantine
Status:
TERMINATED
Status Verified Date:
2021-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not due to safety but due to a lack of efficacy at the 5 mg azeliragon dose
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
STEADFAST
Brief Summary:
This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimers disease Patients will receive either azeliragon or placebo with a patients participation lasting approximately 18 months
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None